These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25654736)

  • 1. Bladder cancer: molecular determinants of personalized therapy.
    Lopez-Beltran A; Santoni M; Massari F; Ciccarese C; Tortora G; Cheng L; Moch H; Scarpelli M; Reymundo C; Montironi R
    Curr Drug Targets; 2015; 16(2):115-24. PubMed ID: 25654736
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A place for precision medicine in bladder cancer: targeting the FGFRs.
    di Martino E; Tomlinson DC; Williams SV; Knowles MA
    Future Oncol; 2016 Oct; 12(19):2243-63. PubMed ID: 27381494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision and predictive medicine in urothelial cancer: are we making progress?
    Bellmunt J; Orsola A; Sonpavde G
    Eur Urol; 2015 Oct; 68(4):547-9. PubMed ID: 25935702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathology of urothelial carcinoma.
    Lopez-Beltran A; Cimadamore A; Montironi R; Cheng L
    Hum Pathol; 2021 Jul; 113():67-83. PubMed ID: 33887300
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Kacew A; Sweis RF
    Front Immunol; 2020; 11():575258. PubMed ID: 33224141
    [No Abstract]   [Full Text] [Related]  

  • 6. Targeted therapy for advanced urothelial cancer of the bladder: where do we stand?
    Zhu Z; Shen Z; Xu C
    Anticancer Agents Med Chem; 2012 Nov; 12(9):1081-7. PubMed ID: 22583418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
    Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
    Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Whole-exome sequencing reveals potential mechanisms of drug resistance to FGFR3-TACC3 targeted therapy and subsequent drug selection: towards a personalized medicine.
    Tong Z; Yan C; Dong YA; Yao M; Zhang H; Liu L; Zheng Y; Zhao P; Wang Y; Fang W; Zhang F; Jiang W
    BMC Med Genomics; 2020 Sep; 13(1):138. PubMed ID: 32957974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Functional Genetic Screen Identifies the Phosphoinositide 3-kinase Pathway as a Determinant of Resistance to Fibroblast Growth Factor Receptor Inhibitors in FGFR Mutant Urothelial Cell Carcinoma.
    Wang L; Šuštić T; Leite de Oliveira R; Lieftink C; Halonen P; van de Ven M; Beijersbergen RL; van den Heuvel MM; Bernards R; van der Heijden MS
    Eur Urol; 2017 Jun; 71(6):858-862. PubMed ID: 28108151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fibroblast growth factor receptor-3 in urothelial tumorigenesis.
    Iyer G; Milowsky MI
    Urol Oncol; 2013 Apr; 31(3):303-11. PubMed ID: 22285006
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recent advances in bladder urothelial carcinogenesis].
    Pignot G; le Goux C; Bieche I
    Bull Cancer; 2015 Dec; 102(12):1020-35. PubMed ID: 26617115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel agents in invasive urothelial cancer.
    Balar AV; Milowsky MI
    Clin Adv Hematol Oncol; 2012 Aug; 10(8):504-16. PubMed ID: 23073049
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted agents in second-line bladder cancer therapy.
    Gerullis H; Otto T; Ecke TH
    Anticancer Drugs; 2012 Nov; 23(10):1003-15. PubMed ID: 22914698
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel biomarkers in bladder cancer.
    Cheng ML; Iyer G
    Urol Oncol; 2018 Mar; 36(3):115-119. PubMed ID: 29472156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
    Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
    J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytotoxic and DNA-targeted therapy in urothelial cancer: have we squeezed the lemon enough?
    Balar AV; Milowsky MI
    Cancer; 2015 Jan; 121(2):179-87. PubMed ID: 25091501
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K; Dyrskjøt L; Wiuf C; Jensen JL; Andersen CL; Jensen KM; Ørntoft TF
    Clin Cancer Res; 2005 Nov; 11(21):7709-19. PubMed ID: 16278391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Emerging Molecular Landscape of Urothelial Carcinoma.
    Solomon JP; Hansel DE
    Surg Pathol Clin; 2016 Sep; 9(3):391-404. PubMed ID: 27523968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FGFR3 and TP53 mutations in a prospective cohort of Belarusian bladder cancer patients.
    Smal MP; Rolevich AI; Polyakov SL; Krasny SA; Goncharova RI
    Exp Oncol; 2014 Dec; 36(4):246-51. PubMed ID: 25537218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment.
    Aoun F; Rassy EE; Assi T; Albisinni S; Katan J
    Immunotherapy; 2017 Mar; 9(5):451-460. PubMed ID: 28357911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.